FLUARIXTETRA, quadrivalent seasonal influenza vaccine
Reason for request
» FLUARIXTETRA now has MA for the prevention of seasonal influenza in infants and children, aged from 6 to 35 months.
» In this population, its efficacy and safety profile is comparable overall to that of trivalent influenza vaccines.
» This vaccine targets populations at a risk of severe forms of influenza.
Clinical Added Value
|no clinical added value||